Health screenings and check-ups for new babies are still relevant during the coronavirus outbreak. These check-ups help families to make informed decisions about how to protect their infants. Hence, stakeholders in the newborn screening market are increasing awareness about additional precautions that need to be taken such as in cases of follow-up testing after the screening results are received.
Since healthcare is one of the essential industries worldwide, state and territorial newborn screening programs are being carried out even during the COVID-19 situation. Healthcare providers in the newborn screening market are capitalizing on this opportunity to offer comprehensive services in blood spot screening, hearing, and critical congenital heart disease (CCHD) test. Clinicians in the U.S. are increasing the availability of contact information and listing it on official state pages to keep individuals abreast with all updates.
The newborn screening market is projected to reach the valuation of US$ 3.3 Bn by 2031. This is evident since the number of conditions assessable by newborn screening methods is increasing, resulting in additional cost for the healthcare system. Moreover, lack of data on long-term consequences of new conditions and scarce follow-up information for screened conditions are hampering the decision making process of healthcare providers. Hence, there is a need to standardize valuation techniques for pediatric health states in the newborn screening market.
There is a need to clarify methodological strengths and flaws in cost effectiveness and cost utility analysis of new pediatric health states.
Companies in the newborn screening market are focusing on reducing the morbidity and mortality associated with heritable disorders in newborns and children. Altarum - a non-profit research and consulting organization has been selected by the Health Resources and Services Administration (HRSA) to lead the Innovations in Newborn Screening Interoperability Resource Center. Such initiatives explain why the newborn screening market is expected to advance at a robust CAGR of ~11% during the forecast period.
In order to improve medical outcomes of newborns and children, healthcare providers are taking efforts to enhance the connectivity between state public health newborn screening programs and healthcare providers. This is being achieved with the help of information management and technical assistance for newborn screening programs.
Healthcare providers in the newborn screening market are setting their collaboration wheels in motion to assess the current state of pediatric screening. Rare disease-focused organizations such as the EveryLife Foundation for Rare Diseases, Retrophin, Inc., BioMarin Pharmaceutical Inc., Orchard Therapeutics Inc., and Sarepta Therapeutics have joined forces to evaluate the capacity of newborn screening in the U.S. Timely diagnosis to all newborns who may benefit from new treatments requires careful evaluation from healthcare organizations.
The evaluation by organizations in the newborn screening market will ensure policy recommendations that enable equitable access to newborn screening for all babies in the U.S.
Companies in the newborn screening market are expanding their revenue streams for babies with rare diseases. The European Commission is gaining recognition for shortening the path to rare disease diagnosis by increasing funding and tender opportunities for newborn screening and digital technologies. This is evident since thousands of distinct rare diseases are affecting a significant amount of newborns in Europe.
Moreover, Nigeria is gaining popularity for introducing its $2 10-minute rapid point-of-care tool, which has the potential to transform sickle cell screening for newborns. Thus, healthcare providers are unlocking growth opportunities in Africa to reduce child mortality with the help of innovations in sickle cell screening. The integration of newborn screening into existing primary healthcare immunization programs is being achieved within limited resources in Africa.
Analysts’ Viewpoint
The safe follow-up on newborn screening results has become a priority for healthcare providers and individuals during the COVID-19 outbreak. Rapid point-of-care tools are replacing conventional screening methods of collecting blood samples on a filter paper in cases of newborns suffering from sickle cell anemia. Despite many achievements, significant delays between the screening and the availability of the treatment are inhibiting growth of the newborn screening market. Hence, healthcare organizations should collaborate on R&D to make advancements in diagnostic medical technologies to reduce morbidity and mortality rate of newborns. Efforts should be made to increase the connectivity between state public health newborn screening programs and healthcare providers.
Newborn Screening Market – Segmentation
TMR’s study on the global newborn screening market includes information divided into four segments: product, test type, end user, and region. Changing industry trends and other crucial market dynamics associated with these segments of the global newborn screening market are discussed in detail.
| Product |
|
| Test Type |
|
| End User |
|
| Region |
|
Newborn screening market is projected to reach the valuation of US$ 3.3 Bn by 2031
Newborn screening market is projected to expand at a CAGR of ~11% from 2021 to 2031
Newborn screening market is driven by rise in prevalence and incidence of critical congenital heart diseases across the globe
The instruments segment dominated the global newborn screening market and the trend is likely to continue during the forecast period
Key players in the global newborn screening market include PerkinElmer, Inc., Trivitron Healthcare, Natus Medical Incorporated, Medtronic Plc, Thermo Fisher Scientific, Inc
1. Preface
1.1. Report Scope and Market Segmentation
1.2. Research Highlights
2. Assumptions and Research Methodology
2.1. Assumptions and Acronyms Used
2.2. Research Methodology
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Dynamics
4.2.1. Drivers
4.2.2. Restraints
4.2.3. Opportunity
4.3. Global Newborn Screening Market Forecast
4.4. Global Newborn Screening Market Outlook
5. Market Outlook
5.1. Key Industry Events (mergers, acquisitions, partnerships, collaborations, etc.)
5.2. COVID-19 Pandemic Impact on Industry (value chain and short / mid / long term impact)
5.3. Overview of the Neonatal Research Funding/Grants
6. Global Newborn Screening Market Analysis, by Product
6.1. Introduction
6.2. Global Newborn Screening Market Value Share and Attractiveness Analysis, by Product
6.3. Global Newborn Screening Market Forecast, by Product
6.3.1. Instruments
6.3.1.1. Tabletop
6.3.1.2. Point-of-Care Testing
6.3.2. Assay Kits
6.4. Global Newborn Screening Market Analysis, by Product
7. Global Newborn Screening Market Analysis, by Test Type
7.1. Introduction
7.2. Global Newborn Screening Market Value Share and Attractiveness Analysis, by Test Type
7.3. Global Newborn Screening Market Forecast, by Test Type
7.3.1. Dry Blood Spot Test
7.3.2. Hearing Screen Test
7.3.3. Critical Congenital Heart Disease (CCHD) Test
7.3.4. X-ray or CT Scan
7.3.5. Electrocardiogram (ECG) Test
7.3.6. Others
7.4. Global Newborn Screening Market Analysis, by Test Type
8. Global Newborn Screening Market Analysis, by End-user
8.1. Introduction
8.2. Global Newborn Screening Market Value Share and Attractiveness Analysis, by End-user
8.3. Global Newborn Screening Market Forecast, by End-user
8.3.1. Hospitals
8.3.2. Diagnostic Centers
8.3.3. Maternity & Specialty Clinics
8.3.4. Others
8.4. Global Newborn Screening Market Analysis, by End-user
9. Global Newborn Screening Market Analysis, by Region
9.1. Global Newborn Screening Market Scenario, by Region/Country
9.2. Global Newborn Screening Market Value Share and Attractiveness Analysis, by Region
9.3. Global Newborn Screening Market Forecast, by Region
9.3.1. North America
9.3.2. Europe
9.3.3. Asia Pacific
9.3.4. Latin America
9.3.5. Middle East & Africa
10. North America Newborn Screening Market Analysis
10.1. North America Newborn Screening Market Overview
10.2. North America Newborn Screening Market Value Share and Attractiveness Analysis, by Country
10.3. North America Newborn Screening Market Forecast, by Country
10.3.1. U.S.
10.3.2. Canada
10.4. North America Newborn Screening Market Value Share and Attractiveness Analysis, by Product
10.5. North America Newborn Screening Market Forecast, by Product
10.5.1. Instruments
10.5.1.1. Tabletop
10.5.1.2. Point-of-Care Testing
10.5.2. Assay Kits
10.6. North America Newborn Screening Market Value Share and Attractiveness Analysis, by Test Type
10.7. North America Newborn Screening Market Forecast, by Test Type
10.7.1. Dry Blood Spot Test
10.7.2. Hearing Screen Test
10.7.3. Critical Congenital Heart Disease (CCHD) Test
10.7.4. X-ray or CT Scan
10.7.5. Electrocardiogram (ECG) Test
10.7.6. Others
10.8. North America Newborn Screening Market Value Share and Attractiveness Analysis, by End-user
10.9. North America Newborn Screening Market Forecast, by End-user
10.9.1. Hospitals
10.9.2. Diagnostic Centers
10.9.3. Maternity & Specialty Clinics
10.9.4. Others
11. Europe Newborn Screening Market Analysis
11.1. Europe Newborn Screening Market Overview
11.2. Europe Newborn Screening Market Value Share and Attractiveness Analysis, by Country/Sub-region
11.3. Europe Newborn Screening Market Forecast, by Country/Sub-region
11.3.1. Germany
11.3.2. France
11.3.3. U.K.
11.3.4. Italy
11.3.5. Spain
11.3.6. Rest of Europe
11.4. Europe Newborn Screening Market Value Share and Attractiveness Analysis, by Product
11.5. Europe Newborn Screening Market Forecast, by Product
11.5.1. Instruments
11.5.1.1. Tabletop
11.5.1.2. Point-of-Care Testing
11.5.2. Assay Kits
11.6. Europe Newborn Screening Market Value Share and Attractiveness Analysis, by Test Type
11.7. Europe Newborn Screening Market Forecast, by Test Type
11.7.1. Dry Blood Spot Test
11.7.2. Hearing Screen Test
11.7.3. Critical Congenital Heart Disease (CCHD) Test
11.7.4. X-ray or CT Scan
11.7.5. Electrocardiogram (ECG) Test
11.7.6. Others
11.8. Europe Newborn Screening Market Value Share and Attractiveness Analysis, by End-user
11.9. Europe Newborn Screening Market Forecast, by End-user
11.9.1. Hospitals
11.9.2. Diagnostic Centers
11.9.3. Maternity & Specialty Clinics
11.9.4. Others
12. Asia Pacific Newborn Screening Market Analysis
12.1. Asia Pacific Newborn Screening Market Overview
12.2. Asia Pacific Newborn Screening Market Value Share and Attractiveness Analysis, by Country/Sub-region
12.3. Asia Pacific Newborn Screening Market Forecast, by Country/Sub-region
12.3.1. Japan
12.3.2. China
12.3.3. India
12.3.4. South Korea
12.3.5. Rest of Asia Pacific
12.4. Asia Pacific Newborn Screening Market Value Share and Attractiveness Analysis, by Product
12.5. Asia Pacific Newborn Screening Market Forecast, by Product
12.5.1. Instruments
12.5.1.1. Tabletop
12.5.1.2. Point-of-Care Testing
12.5.2. Assay Kits
12.6. Asia Pacific Newborn Screening Market Value Share and Attractiveness Analysis, by Test Type
12.7. Asia Pacific Newborn Screening Market Forecast, by Test Type
12.7.1. Dry Blood Spot Test
12.7.2. Hearing Screen Test
12.7.3. Critical Congenital Heart Disease (CCHD) Test
12.7.4. X-ray or CT Scan
12.7.5. Electrocardiogram (ECG) Test
12.7.6. Others
12.8. Asia Pacific Newborn Screening Market Value Share and Attractiveness Analysis, by End-user
12.9. Asia Pacific Newborn Screening Market Forecast, by End-user
12.9.1. Hospitals
12.9.2. Diagnostic Centers
12.9.3. Maternity & Specialty Clinics
12.9.4. Others
13. Latin America Newborn Screening Market Analysis
13.1. Latin America Newborn Screening Market Overview
13.2. Latin America Newborn Screening Market Value Share and Attractiveness Analysis, by Country/Sub-region
13.3. Latin America Newborn Screening Market Forecast, by Country/Sub-region
13.3.1. Brazil
13.3.2. Mexico
13.3.3. Rest of Latin America
13.4. Latin America Newborn Screening Market Value Share and Attractiveness Analysis, by Product
13.5. Latin America Newborn Screening Market Forecast, by Product
13.5.1. Instruments
13.5.1.1. Tabletop
13.5.1.2. Point-of-Care Testing
13.5.2. Assay Kits
13.6. Latin America Newborn Screening Market Value Share and Attractiveness Analysis, by Test Type
13.7. Latin America Newborn Screening Market Forecast, by Test Type
13.7.1. Dry Blood Spot Test
13.7.2. Hearing Screen Test
13.7.3. Critical Congenital Heart Disease (CCHD) Test
13.7.4. X-ray or CT Scan
13.7.5. Electrocardiogram (ECG) Test
13.7.6. Others
13.8. Latin America Newborn Screening Market Value Share and Attractiveness Analysis, by End-user
13.9. Latin America Newborn Screening Market Forecast, by End-user
13.9.1. Hospitals
13.9.2. Diagnostic Centers
13.9.3. Maternity & Specialty Clinics
13.9.4. Others
14. Middle East & Africa Newborn Screening Market Analysis
14.1. Middle East & Africa Newborn Screening Market Overview
14.2. Middle East & Africa Newborn Screening Market Value Share and Attractiveness Analysis, by Country/Sub-region
14.3. Middle East & Africa Newborn Screening Market Forecast, by Country/Sub-region
14.3.1. GCC Countries
14.3.2. South Africa
14.3.3. Rest of Middle East & Africa
14.4. Middle East & Africa Newborn Screening Market Value Share and Attractiveness Analysis, by Product
14.5. Middle East & Africa Newborn Screening Market Forecast, by Product
14.5.1. Instruments
14.5.2. Tabletop
14.5.3. Point-of-Care Testing
14.5.4. Assay Kits
14.6. Middle East & Africa Newborn Screening Market Value Share and Attractiveness Analysis, by Test Type
14.7. Middle East & Africa Newborn Screening Market Forecast, by Test Type
14.7.1. Dry Blood Spot Test
14.7.2. Hearing Screen Test
14.7.3. Critical Congenital Heart Disease (CCHD) Test
14.7.4. X-ray or CT Scan
14.7.5. Electrocardiogram (ECG) Test
14.7.6. Others
14.8. Middle East & Africa Newborn Screening Market Value Share and Attractiveness Analysis, by End-user
14.9. Middle East & Africa Newborn Screening Market Forecast, by End-user
14.9.1. Hospitals
14.9.2. Diagnostic Centers
14.9.3. Maternity & Specialty Clinics
14.9.4. Others
15. Competition Landscape
15.1. Competition Matrix
15.2. Company Share Analysis, 2019
15.3. Company Profiles
15.3.1. PerkinElmer, Inc.
15.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.1.2. Financial Overview
15.3.1.3. Product Portfolio
15.3.1.4. SWOT Analysis
15.3.1.5. Strategic Overview
15.3.2. Trivitron Healthcare
15.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.2.2. Product Portfolio
15.3.2.3. SWOT Analysis
15.3.2.4. Strategic Overview
15.3.3. Natus Medical Incorporated
15.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.3.2. Financial Overview
15.3.3.3. Product Portfolio
15.3.3.4. SWOT Analysis
15.3.3.5. Strategic Overview
15.3.4. Medtronic plc
15.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.4.2. Financial Overview
15.3.4.3. Product Portfolio
15.3.4.4. SWOT Analysis
15.3.4.5. Strategic Overview
15.3.5. Thermo Fisher Scientific, Inc.
15.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.5.2. Financial Overview
15.3.5.3. Product Portfolio
15.3.5.4. SWOT Analysis
15.3.5.5. Strategic Overview
15.3.6. Bio-Rad Laboratories, Inc.
15.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.6.2. Financial Overview
15.3.6.3. Product Portfolio
15.3.6.4. SWOT Analysis
15.3.6.5. Strategic Overview
15.3.7. GE Healthcare (General Electric Company)
15.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.7.2. Financial Overview
15.3.7.3. Product Portfolio
15.3.7.4. SWOT Analysis
15.3.7.5. Strategic Overview
15.3.8. ZenTech S.A.
15.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.8.2. Product Portfolio
15.3.8.3. SWOT Analysis
15.3.8.4. Strategic Overview
15.3.9. MP BIOMEDICALS
15.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.9.2. Product Portfolio
15.3.9.3. SWOT Analysis
15.3.9.4. Strategic Overview
15.3.10. Baebies, Inc.
15.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.10.2. Product Portfolio
15.3.10.3. SWOT Analysis
15.3.10.4. Strategic Overview
15.3.11. Masimo
15.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.11.2. Financial Overview
15.3.11.3. Product Portfolio
15.3.11.4. SWOT Analysis
15.3.11.5. Strategic Overview
List of Tables
Table 01: Global Newborn Screening Market Value (US$ Mn) Forecast, by Product, 2017–2031
Table 02: Global Newborn Screening Market Value (US$ Mn) Forecast, by Instruments, 2017–2031
Table 03: Global Newborn Screening Market Value (US$ Mn) Forecast, by Test Type, 2017–2031
Table 04: Global Newborn Screening Market Value (US$ Mn) Forecast, by End-user, 2017–2031
Table 05: Global Newborn Screening Market Value (US$ Mn) Forecast, by Region, 2017–2031
Table 06: North America Newborn Screening Market Value (US$ Mn) Forecast, by Country, 2017–2031
Table 07: North America Newborn Screening Market Value (US$ Mn) Forecast, by Product, 2017–2031
Table 08: North America Newborn Screening Market Value (US$ Mn) Forecast, by Instruments, 2017–2031
Table 09: North America Newborn Screening Market Value (US$ Mn) Forecast, by Test Type, 2017–2031
Table 10: North America Newborn Screening Market Value (US$ Mn) Forecast, by End-user, 2017–2031
Table 11: Europe Newborn Screening Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 12: Europe Newborn Screening Market Value (US$ Mn) Forecast, by Product, 2017–2031
Table 13: Europe Newborn Screening Market Value (US$ Mn) Forecast, by Instruments, 2017–2031
Table 14: Europe Newborn Screening Market Value (US$ Mn) Forecast, by Test Type, 2017–2031
Table 15: Europe Newborn Screening Market Value (US$ Mn) Forecast, by End-user, 2017–2031
Table 16: Asia Pacific Newborn Screening Market Revenue (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 17: Asia Pacific Newborn Screening Market Size (US$ Mn) Forecast, by Product, 2017–2031
Table 18: Asia Pacific Newborn Screening Market Size (US$ Mn) Forecast, by Instruments, 2017–2031
Table 19: Asia Pacific Newborn Screening Market Size (US$ Mn) Forecast, by Test Type, 2017–2031
Table 20: Asia Pacific Newborn Screening Market Size (US$ Mn) Forecast, by End-user, 2017–2031
Table 21: Latin America Newborn Screening Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 22: Latin America Newborn Screening Market Value (US$ Mn) Forecast, by Product, 2017–2031
Table 23: Latin America Newborn Screening Market Value (US$ Mn) Forecast, by Instruments, 2017–2031
Table 24: Latin America Newborn Screening Market Value (US$ Mn) Forecast, by Test Type, 2017–2031
Table 25: Latin America Newborn Screening Market Value (US$ Mn) Forecast, by End-user, 2017–2031
Table 26: Middle East & Africa Newborn Screening Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 27: Middle East & Africa Newborn Screening Market Value (US$ Mn) Forecast, by Product, 2017–2031
Table 28: Middle East & Africa Newborn Screening Market Value (US$ Mn) Forecast, by Instruments, 2017–2031
Table 29: Middle East & Africa Newborn Screening Market Value (US$ Mn) Forecast, by Test Type, 2017–2031
Table 30: Middle East & Africa Newborn Screening Market Value (US$ Mn) Forecast, by End-user, 2017–2031
List of Figures
Figure 01: Global Newborn Screening Market Value (US$ Mn) Forecast, 2017–2031
Figure 02: Global Newborn Screening Market Value Share, by Product, 2019
Figure 03: Global Newborn Screening Market Value Share, by End-user, 2019
Figure 04: Global Newborn Screening Market Value Share, by Test Type, 2019
Figure 05: Global Newborn Screening Market Value Share, by Region, 2019
Figure 06: Global Newborn Screening Market Value Share Analysis, by Product, 2019 and 2031
Figure 07: Global Newborn Screening Market Revenue (US$ Mn), by Instruments, 2017–2031
Figure 08: Global Newborn Screening Market Revenue (US$ Mn), by Assay Kits, 2017–2031
Figure 09: Global Newborn Screening Market Attractiveness Analysis, by Product, 2021–2031
Figure 10: Global Newborn Screening Market Value Share Analysis, by Test Type, 2019 and 2031
Figure 11: Global Newborn Screening Market Revenue (US$ Mn), by Dry Blood Spot Test, 2017–2031
Figure 12: Global Newborn Screening Market Revenue (US$ Mn), by Hearing Screen Test, 2017–2031
Figure 13: Global Newborn Screening Market Revenue (US$ Mn), by Critical Congenital Heart Disease (CCHD) Test, 2017–2031
Figure 14: Global Newborn Screening Market Revenue (US$ Mn), by X-ray or CT Scan, 2017–2031
Figure 15: Global Newborn Screening Market Revenue (US$ Mn), by Electrocardiogram (ECG) Test, 2017–2031
Figure 16: Global Newborn Screening Market Revenue (US$ Mn), by Others, 2017–2031
Figure 17: Global Newborn Screening Market Attractiveness Analysis, by Test Type, 2021–2031
Figure 18: Global Newborn Screening Market Value Share Analysis, by End-user, 2019 and 2031
Figure 19: Global Newborn Screening Market Revenue (US$ Mn), by Hospitals, 2017–2031
Figure 20: Global Newborn Screening Market Revenue (US$ Mn), by Diagnostic Centers, 2017–2031
Figure 21: Global Newborn Screening Market Revenue (US$ Mn), by Maternity & Specialty Clinics, 2017–2031
Figure 22: Global Newborn Screening Market Revenue (US$ Mn), by Diagnostic Centers, 2017–2031
Figure 23: Global Newborn Screening Market Attractiveness Analysis, by End-user, 2021–2031
Figure 24: Global Newborn Screening Market Value Share Analysis, by Region, 2019 and 2031
Figure 25: Global Newborn Screening Market Analysis, by Region
Figure 26: North America Newborn Screening Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031
Figure 27: North America Newborn Screening Market Value Share (%), by Country, 2019 and 2031
Figure 28: North America Newborn Screening Market Attractiveness, by Country, 2021–2031
Figure 29: North America Newborn Screening Market Value Share Analysis, by Product, 2019 and 2031
Figure 30: North America Newborn Screening Market Attractiveness, by Product, 2021–2031
Figure 31: North America Newborn Screening Market Value Share Analysis, by Test Type, 2019 and 2031
Figure 32: North America Newborn Screening Market Attractiveness, by Test Type, 2021–2031
Figure 33: North America Newborn Screening Market Value Share Analysis, by End-user, 2019 and 2031
Figure 34: North America Newborn Screening Market Attractiveness, by End-user, 2021–2031
Figure 35: Europe Newborn Screening Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031
Figure 36: Europe Newborn Screening Market Value Share (%), by Country/Sub-region, 2019 and 2031
Figure 37: Europe Newborn Screening Market Attractiveness, by Country/Sub-region, 2021–2031
Figure 38: Europe Newborn Screening Market Value Share Analysis, by Product, 2019 and 2031
Figure 39: Europe Newborn Screening Market Attractiveness, by Product, 2021–2031
Figure 40: Europe Newborn Screening Market Value Share Analysis, by Test Type, 2019 and 2031
Figure 41: Europe Newborn Screening Market Attractiveness, by Test Type, 2021–2031
Figure 42: Europe Newborn Screening Market Value Share Analysis, by End-user, 2019 and 2031
Figure 43: Europe Newborn Screening Market Attractiveness, by End-user, 2021–2031
Figure 44: Asia Pacific Newborn Screening Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031
Figure 45: Asia Pacific Newborn Screening Market Value Share (%), by Country/Sub-region, 2019 and 2031
Figure 46: Asia Pacific Newborn Screening Market Attractiveness, by Country/Sub-region, 2021–2031
Figure 47: Asia Pacific Newborn Screening Market Value Share Analysis, by Product, 2019 and 2031
Figure 48: Asia Pacific Newborn Screening Market Attractiveness, by Product, 2021–2031
Figure 49: Asia Pacific Newborn Screening Market Value Share Analysis, by Test Type, 2019 and 2031
Figure 50: Asia Pacific Newborn Screening Market Attractiveness, by Test Type, 2021–2031
Figure 51: Asia Pacific Newborn Screening Market Value Share Analysis, by End-user, 2019 and 2031
Figure 52: Asia Pacific Newborn Screening Market Attractiveness, by End-user, 2021–2031
Figure 53: Latin America Newborn Screening Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031
Figure 54: Latin America Newborn Screening Market Value Share (%), by Country/Sub-region, 2019 and 2031
Figure 55: Latin America Newborn Screening Market Attractiveness, by Country/Sub-region, 2021–2031
Figure 56: Latin America Newborn Screening Market Value Share Analysis, by Product, 2019 and 2031
Figure 57: Latin America Newborn Screening Market Attractiveness, by Product, 2021–2031
Figure 58: Latin America Newborn Screening Market Value Share Analysis, by Test Type, 2019 and 2031
Figure 59: Latin America Newborn Screening Market Attractiveness, by Test Type, 2021–2031
Figure 60: Latin America Newborn Screening Market Value Share Analysis, by End-user, 2019 and 2031
Figure 61: Latin America Newborn Screening Market Attractiveness, by End-user, 2021–2031
Figure 62: Middle East & Africa Newborn Screening Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031
Figure 63: Middle East & Africa Newborn Screening Market Value Share (%), by Country/Sub-region, 2019 and 2031
Figure 64: Middle East & Africa Newborn Screening Market Attractiveness, by Country/Sub-region, 2021–2031
Figure 65: Middle East & Africa Newborn Screening Market Value Share Analysis, by Product, 2019 and 2031
Figure 66: Middle East & Africa Newborn Screening Market Attractiveness, by Product, 2021–2031
Figure 67: Middle East & Africa Newborn Screening Market Value Share Analysis, by Test Type, 2019 and 2031
Figure 68: Middle East & Africa Newborn Screening Market Attractiveness, by Test Type, 2021–2031
Figure 69: Middle East & Africa Newborn Screening Market Value Share Analysis, by End-user, 2019 and 2031
Figure 70: Middle East & Africa Newborn Screening Market Attractiveness, by End-user, 2021–2031
Figure 71: Global Newborn Screening Market Share, by Company, 2019
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
Newborn Screening Market Forecast, 2021-2031
